Skip to main content
Erschienen in: Rheumatology International 2/2015

01.02.2015 | Original Article - Observational Research

An investigation into the relationship between anti-Helicobacter pylori and anti-Saccharomyces cerevisiae antibodies in patients with axial spondyloarthritis and Crohn disease

verfasst von: Igor Kunze Rodrigues, Michele Andrigueti, Ione Dilma de Oliveira Gil, Leonardo de Lucca Schiavon, Kenia Rodrigues de Andrade, Ivanio Alves Pereira, Gláucio Ricardo Werner de Castro, Adriana Fontes Zimmermann, Luciano Nascimento Saporiti, Maria Luiza Bazzo, Fabricio Souza Neves

Erschienen in: Rheumatology International | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Spondyloarthritis (SpA) is a musculoskeletal inflammatory disease linked with immune responses to intestinal microbiota, and subclinical intestinal ulcerations that are closely related to inflammatory bowel diseases. Helicobacter pylori is a common cause of gastroduodenal ulceration, and anti-Saccharomyces cerevisiae antibodies (ASCA) are associated with intestinal inflammation in both Crohn disease (CD) and SpA. We investigated the relationship between H. pylori and ASCA. Ninety-one patients with axial SpA and forty with CD were included. ASCA IgG/IgA and anti-H. pylori IgG titers were assessed by ELISA. The proportion of ASCA+ patients in the positive and negative anti-H. pylori IgG groups with SpA and CD were compared using Chi-square tests, and correlations were evaluated using the Spearman’s coefficient. Anti-H. pylori IgG titers were significantly negatively correlated with the ASCA IgG (r = −0.563, p < 0.001) and IgA (r = −0.342, p = 0.019) titers in the axial SpA patients. The same pattern of negative correlation was also observed in the CD patients. Anti-H. pylori+ serology was significantly more frequent in axial SpA patients than in those with CD (52.4 vs. 18.4 %, p < 0.001), while ASCA+ serology was significantly more frequent in CD patients than in SpA patients. A negative correlation between the anti-H. pylori titers and ASCA was found for axial SpA and CD. Anti-H. pylori+ serology was more frequent in SpA than in CD, while ASCA positivity was more frequent in CD patients than in those with SpA. A possible influence of H. pylori on the development of ASCA needs further investigation.
Literatur
2.
Zurück zum Zitat Tam LS, Gu J, Yu D (2010) Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol 6:399–405PubMedCrossRef Tam LS, Gu J, Yu D (2010) Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol 6:399–405PubMedCrossRef
3.
Zurück zum Zitat Zeidler H, Calin A, Amor B (2011) A historical perspective of the spondyloarthritis. Curr Opin Rheumatol 23:327–333PubMedCrossRef Zeidler H, Calin A, Amor B (2011) A historical perspective of the spondyloarthritis. Curr Opin Rheumatol 23:327–333PubMedCrossRef
4.
Zurück zum Zitat Thjodleifsson B, Geirsson AJ, Björnsson S, Bjarnason I (2007) A common genetic background for inflammatory bowel disease and ankylosing spondylitis: a genealogic study in Iceland. Arthritis Rheum 56:2633–2639PubMedCrossRef Thjodleifsson B, Geirsson AJ, Björnsson S, Bjarnason I (2007) A common genetic background for inflammatory bowel disease and ankylosing spondylitis: a genealogic study in Iceland. Arthritis Rheum 56:2633–2639PubMedCrossRef
5.
Zurück zum Zitat Laukens D, Georges M, Libioulle C, Sandor C, Mni M, Cruyssen BV, Peeters H, Elewaut D, De Vos M (2010) Evidence for significant overlap between common risk variants for Crohn’s disease and ankylosing spondylitis. PLoS ONE 5:e13795PubMedCentralPubMedCrossRef Laukens D, Georges M, Libioulle C, Sandor C, Mni M, Cruyssen BV, Peeters H, Elewaut D, De Vos M (2010) Evidence for significant overlap between common risk variants for Crohn’s disease and ankylosing spondylitis. PLoS ONE 5:e13795PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Shivashankar R, Loftus EV Jr, Tremaine WJ, Bongartz T, Harmsen WS, Zinsmeister AR, Matteson EL (2012) Incidence of spondyloarthropathy in patients with Crohn’s disease: a population-based study. J Rheumatol 39:2148–2152PubMedCentralPubMedCrossRef Shivashankar R, Loftus EV Jr, Tremaine WJ, Bongartz T, Harmsen WS, Zinsmeister AR, Matteson EL (2012) Incidence of spondyloarthropathy in patients with Crohn’s disease: a population-based study. J Rheumatol 39:2148–2152PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, Schatteman L, Elewaut D (1995) The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 22:2273–2278PubMed Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, Schatteman L, Elewaut D (1995) The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 22:2273–2278PubMed
8.
Zurück zum Zitat Altomonte L, Zoli A, Veneziani A, Mirone L, Santacesaria G, Chiarelli C, Federico F, Massi G, Magaro M (1994) Clinically silent inflammatory gut lesions in undifferentiated spondyloarthropathies. Clin Rheumatol 13:565–570PubMedCrossRef Altomonte L, Zoli A, Veneziani A, Mirone L, Santacesaria G, Chiarelli C, Federico F, Massi G, Magaro M (1994) Clinically silent inflammatory gut lesions in undifferentiated spondyloarthropathies. Clin Rheumatol 13:565–570PubMedCrossRef
9.
Zurück zum Zitat Leirisalo-Repo M, Turunen U, Stenman S, Helenius P, Seppälä K (1994) High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum 37:23–31PubMedCrossRef Leirisalo-Repo M, Turunen U, Stenman S, Helenius P, Seppälä K (1994) High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum 37:23–31PubMedCrossRef
10.
Zurück zum Zitat Simenon G, Van Gossum A, Adler M, Rickaert F, Appelboom T (1990) Macroscopic and microscopic gut lesions in seronegative spondyloarthropathies. J Rheumatol 17:1491–1494PubMed Simenon G, Van Gossum A, Adler M, Rickaert F, Appelboom T (1990) Macroscopic and microscopic gut lesions in seronegative spondyloarthropathies. J Rheumatol 17:1491–1494PubMed
11.
Zurück zum Zitat Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, Schatteman L, Gyselbrecht L, Elewaut D (1995) The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 22:2279–2284PubMed Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, Schatteman L, Gyselbrecht L, Elewaut D (1995) The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 22:2279–2284PubMed
12.
Zurück zum Zitat Main J, McKenzie H, Yeaman GR, Kerr MA, Robson D, Pennington CR, Parratt D (1988) Antibody to Saccharomyces cerevisiae (bakers’ yeast) in Crohn’s disease. Brit Med J 297:1105–1106PubMedCentralPubMedCrossRef Main J, McKenzie H, Yeaman GR, Kerr MA, Robson D, Pennington CR, Parratt D (1988) Antibody to Saccharomyces cerevisiae (bakers’ yeast) in Crohn’s disease. Brit Med J 297:1105–1106PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Prideaux L, De Crux P, Ng SC, Kamm MA (2012) Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 18:1340–1355PubMedCrossRef Prideaux L, De Crux P, Ng SC, Kamm MA (2012) Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 18:1340–1355PubMedCrossRef
14.
Zurück zum Zitat Andretta M, Vieira TD, Nishiara R, Skare TL (2013) Anti-Saccharomyces cerevisiae (ASCA) and anti-endomysial antibodies in spondyloarthritis. Rheumatol Int 32:551–554CrossRef Andretta M, Vieira TD, Nishiara R, Skare TL (2013) Anti-Saccharomyces cerevisiae (ASCA) and anti-endomysial antibodies in spondyloarthritis. Rheumatol Int 32:551–554CrossRef
15.
Zurück zum Zitat Aydin SZ, Atagunduz P, Temel M, Bicakcigil M, Tasan D, Direskeneli H (2008) Anti-Saccharomycescerevisae antibodies (ASCA) in spondyloarthropathies: a reassessment. Rheumatology 47:142–144PubMedCrossRef Aydin SZ, Atagunduz P, Temel M, Bicakcigil M, Tasan D, Direskeneli H (2008) Anti-Saccharomycescerevisae antibodies (ASCA) in spondyloarthropathies: a reassessment. Rheumatology 47:142–144PubMedCrossRef
16.
Zurück zum Zitat Sellin JH, Shah RS (2012) The promise and pitfalls of serologic testing in inflammatory bowel disease. Gastroenterol Clin North Am 41:463–482PubMedCrossRef Sellin JH, Shah RS (2012) The promise and pitfalls of serologic testing in inflammatory bowel disease. Gastroenterol Clin North Am 41:463–482PubMedCrossRef
19.
Zurück zum Zitat Malaty HM, El-Kasabany A, Graham DY, Miller CC, Reddy SG, Srinivasan SR, Yamaoka Y, Berenson GS (2002) Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. Lancet 359:931–935PubMedCrossRef Malaty HM, El-Kasabany A, Graham DY, Miller CC, Reddy SG, Srinivasan SR, Yamaoka Y, Berenson GS (2002) Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. Lancet 359:931–935PubMedCrossRef
20.
Zurück zum Zitat Malfertheiner P, Megraud F, O’Morain CA et al (2012) Management of Helicobacter pylori infection—the Maastricht IV/Florence consensus report. Gut 61:646–664PubMedCrossRef Malfertheiner P, Megraud F, O’Morain CA et al (2012) Management of Helicobacter pylori infection—the Maastricht IV/Florence consensus report. Gut 61:646–664PubMedCrossRef
21.
Zurück zum Zitat Di Leo V, D’Inca R, Bettini MB, Podswiadek M, Punzi L, Mastropaolo G, Sturniolo GC (2005) Effect of Helicobacter pylori and eradication therapy on gastrointestinal permeability. Implications for patients with seronegative spondyloarthritis. J Rheumatol 32:295–300PubMed Di Leo V, D’Inca R, Bettini MB, Podswiadek M, Punzi L, Mastropaolo G, Sturniolo GC (2005) Effect of Helicobacter pylori and eradication therapy on gastrointestinal permeability. Implications for patients with seronegative spondyloarthritis. J Rheumatol 32:295–300PubMed
22.
Zurück zum Zitat Lidar M, Langevitz P, Barzilai O, Ram M, Porat-Katz B-S, Bizzaro N, Tonutti E, Maieron R, Chowers Y, Bar-Meir S, Shoenfeld Y (2009) Infectious serologies and autoantibodies in inflammatory bowel disease: insinuations at a true pathogenic role. Ann N Y Acad Sci 1173:640–648PubMedCrossRef Lidar M, Langevitz P, Barzilai O, Ram M, Porat-Katz B-S, Bizzaro N, Tonutti E, Maieron R, Chowers Y, Bar-Meir S, Shoenfeld Y (2009) Infectious serologies and autoantibodies in inflammatory bowel disease: insinuations at a true pathogenic role. Ann N Y Acad Sci 1173:640–648PubMedCrossRef
23.
Zurück zum Zitat Väre PO, Heikius B, Silvennoinen JA, Karttunen R, Niemalä SE, Lehtola JK, Karttunen TJ (2001) Seroprevalence of Helicobacter pylori infection in inflammatory bowel disease: is Helicobacter pylori infection a protective factor? Scand J Gastroenterol 36:1295–1300PubMedCrossRef Väre PO, Heikius B, Silvennoinen JA, Karttunen R, Niemalä SE, Lehtola JK, Karttunen TJ (2001) Seroprevalence of Helicobacter pylori infection in inflammatory bowel disease: is Helicobacter pylori infection a protective factor? Scand J Gastroenterol 36:1295–1300PubMedCrossRef
24.
Zurück zum Zitat Rudwaleit M, van der Heijde D, Landewé R et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783PubMedCrossRef Rudwaleit M, van der Heijde D, Landewé R et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783PubMedCrossRef
25.
Zurück zum Zitat Shinjo SK, Gonçalves R, Gonçalves CR (2006) Measures of clinical assessment in patients with ankylosing spondylitis: review of literature. Rev Bras Reumatol 46:340–346CrossRef Shinjo SK, Gonçalves R, Gonçalves CR (2006) Measures of clinical assessment in patients with ankylosing spondylitis: review of literature. Rev Bras Reumatol 46:340–346CrossRef
26.
Zurück zum Zitat van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewé R (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811–1818PubMedCrossRef van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewé R (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811–1818PubMedCrossRef
27.
Zurück zum Zitat Pfefferle PI, Krämer A (2008) Helicobacter pylori-infection status and childhood living conditions are associated with signs of allergic diseases in an occupational population. Eur J Epidemiol 23:635–640PubMedCrossRef Pfefferle PI, Krämer A (2008) Helicobacter pylori-infection status and childhood living conditions are associated with signs of allergic diseases in an occupational population. Eur J Epidemiol 23:635–640PubMedCrossRef
28.
Zurück zum Zitat Lee YY, Raj SM, Graham DY (2013) Helicobacter pylori infection – a boon or a bane: lessons from studies in a low-prevalence population. Helicobacter 18:338–346PubMedCentralPubMedCrossRef Lee YY, Raj SM, Graham DY (2013) Helicobacter pylori infection – a boon or a bane: lessons from studies in a low-prevalence population. Helicobacter 18:338–346PubMedCentralPubMedCrossRef
29.
Zurück zum Zitat Arnold IC, Dehzad N, Reuter S, Martin H, Becher B, Tauber C, Müller A (2011) Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J Clin Invest 121:3088–3093PubMedCentralPubMedCrossRef Arnold IC, Dehzad N, Reuter S, Martin H, Becher B, Tauber C, Müller A (2011) Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J Clin Invest 121:3088–3093PubMedCentralPubMedCrossRef
30.
Zurück zum Zitat Oertli M, Sundquist M, Hitzler I, Engler DB, Arnold IC, Reuter S, Maxeiner J, Hansson M, Taube C, Quiding-Järbrink M, Müller A (2012) DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection. J Clin Invest 122:1082–1096PubMedCentralPubMedCrossRef Oertli M, Sundquist M, Hitzler I, Engler DB, Arnold IC, Reuter S, Maxeiner J, Hansson M, Taube C, Quiding-Järbrink M, Müller A (2012) DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection. J Clin Invest 122:1082–1096PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Kuipers EJ, Peña AS, Pels NFM, Kurz-Pohlmann E, Meuwissen SGM, van Kamp G, Uyterlinde AM, Pals G (1993) Seroconversion for Helicobacter pylori. Lancet 342:328–331PubMedCrossRef Kuipers EJ, Peña AS, Pels NFM, Kurz-Pohlmann E, Meuwissen SGM, van Kamp G, Uyterlinde AM, Pals G (1993) Seroconversion for Helicobacter pylori. Lancet 342:328–331PubMedCrossRef
32.
Zurück zum Zitat Feldman M, Cryer B, Lee E, Peterson WL (1998) Role of seroconversion in confirming cure of Helicobacter pylori infection. JAMA 280:363–365PubMedCrossRef Feldman M, Cryer B, Lee E, Peterson WL (1998) Role of seroconversion in confirming cure of Helicobacter pylori infection. JAMA 280:363–365PubMedCrossRef
33.
Zurück zum Zitat Hoffman IEA, Demetter P, Peeters M, De Vos M, Mielants H, Veys EM, De Keyser F (2003) Anti-Saccharomyces cerevisiae IgA antibodies are raised on ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis 62:455–459PubMedCentralPubMedCrossRef Hoffman IEA, Demetter P, Peeters M, De Vos M, Mielants H, Veys EM, De Keyser F (2003) Anti-Saccharomyces cerevisiae IgA antibodies are raised on ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis 62:455–459PubMedCentralPubMedCrossRef
Metadaten
Titel
An investigation into the relationship between anti-Helicobacter pylori and anti-Saccharomyces cerevisiae antibodies in patients with axial spondyloarthritis and Crohn disease
verfasst von
Igor Kunze Rodrigues
Michele Andrigueti
Ione Dilma de Oliveira Gil
Leonardo de Lucca Schiavon
Kenia Rodrigues de Andrade
Ivanio Alves Pereira
Gláucio Ricardo Werner de Castro
Adriana Fontes Zimmermann
Luciano Nascimento Saporiti
Maria Luiza Bazzo
Fabricio Souza Neves
Publikationsdatum
01.02.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 2/2015
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-014-3088-x

Weitere Artikel der Ausgabe 2/2015

Rheumatology International 2/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.